Elizabeth Lieschke: 2019 recipient | Leukaemia Foundation

Elizabeth Lieschke: 2019 recipient

Elizabeth Lieschke

Elizabeth Lieschke, Walter and Eliza Hall Institute of Medical Research (Melbourne).
Funding period: 2019-2022.
Project title: Investigating the contributions of cell cycle arrest, cell senescence and cell death in p53 mediated tumour suppression.

This PhD is kindly supported by Bridgestone Australia .

Detailed project summary

Ms Lieschke’s research investigates the mechanism by which tumour suppressor gene, Tp53, prevents the development of leukaemia, lymphoma and other cancers; and the processes by which activation of Tp53 kills malignant cells.

The study aims to understand why some blood cancer cells die, whilst other cancer cells undergo cell cycle arrest/cell senescence and are therefore more likely to relapse following cancer therapy.

Ms Lieschke and team hopes to identify biomarkers that will enable the team to predict the nature of the response of cancer cells to drugs that activate Tp53 and leading to therapies that will be more personalised and targeted.

Mutations in Tp53 occur frequently in blood cancers that relapse following therapy and for these patients, the prognosis is extremely poor. A deeper understanding of the impact of mutations in Tp53 on the expression of critical genes involved in tumour suppression will inform the design of novel therapeutics that could act downstream of Tp53, and efficiently kill mutant Tp53 expressing blood cancers. The team believes such therapies are desperately needed because they would improve the prognosis for blood cancer patients.

Posted on January 13th, 2020

Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.

Share this page

X
X